← Leaderboards
Roger Le Grand
Osivax Sas
$770,114
Attributed
$1,540,227
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $529.9K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$1,540,227 · 1
By mechanism
R01$1,540,227 · 1
Top collaborators
- Florence Nicolas4 shared
Others in their field
Other Rising Stars on “Age Group”
- Joan Grand · Mitre Corporation$32,826,287
- Jeffrey Leintz · National Opinion Research Center$17,634,628
- Jennifer Lee O'Brien · University Of South Florida$10,506,386
- Songthip T. Ounpraseuth · Univ Of Arkansas For Med Scis$10,363,762
- Michael E. Roth · Public Health Institute$8,201,777
- Cathryn Peltz · Henry Ford Health + Michigan State University Health Sciences$7,977,678
Research focus
Age GroupAnimalsAntibodiesAntibody ResponseAntigensAntigen TargetingAvian InfluenzaCd4 Positive T LymphocytesCd8-Positive T-LymphocytesCessation Of LifeConduct Clinical TrialsCostCost EstimateCross ReactivityCurrent PandemicDoseEffectivenessElementsExposure ToFutureGlobal HealthGlycoproteinsGrantAdjuvant
Grant awards (4)
Broad spectrum protection and immune responses induced by an NP-based universal influenza vaccine in heterologous NHP challenge model$370,152
R01 · FY2025 · AI
Broad spectrum protection and immune responses induced by an NP-based universal influenza vaccine in heterologous NHP challenge model$113,911
R01 · FY2025 · AI
Broad spectrum protection and immune responses induced by an NP-based universal influenza vaccine in heterologous NHP challenge model$526,307
R01 · FY2024 · AI
Broad spectrum protection and immune responses induced by an NP-based universal influenza vaccine in heterologous NHP challenge model$529,857
R01 · FY2023 · AI